TÜBİTAK President Prof. Dr. Hasan Mandal stated that the innovative inactive vaccine that Turkish scientists are working on against the new type of corona virus (Covid-19) is also included in the list of the World Health Organization (WHO).
Mandal said in a statement he made at the TÜBİTAK MAM Genetic Engineering and Biotechnology Institute in Gebze that important studies have been carried out in Turkey at the point of vaccine development.
Mandal stated that 7 of these were carried out within the scope of the Covid-19 Turkey Platform and that there are also studies of the private sector, and said, “With the total of these studies, our Minister Mustafa Varank also stated that in the group of vaccine development studies in the world; we are one of the first 3 countries. This is an important achievement. Then comes the question: “Yes, there is work, but are there any results?” Our friends in Erciyes, who are currently in the early stage, have completed the inactive vaccine phase 2 studies. 2 of the vaccines within the scope of the Covid-19 Turkey Platform are currently in phase study, and one will have started phase 1 very soon. ” he spoke.
“OUR VACCINES ARE INNOVATIVE AND CAN ENTER THE WHO LIST”
Mandal pointed out that there are companies that develop very good biotechnological products in Turkey and said:
“They turned themselves into vaccines. We currently have facilities in Turkey that can produce vaccines. They will be able to produce vaccines when the phase studies are completed. We are not talking about next year. We will be able to produce vaccines this year, as long as the phase studies are completed. 2 in the Covid-19 Turkey Platform. Our vaccine is on the World Health Organization list. The vaccine based on virus-like particles (VLP) was included. Last Sunday, our second vaccine, our innovative inactive vaccine, is now included in the WHO list. These are very important. “We are not only vaccinating, we are also opening it to the world. We say that our vaccines are innovative and they can be included in the World Health Organization list.”
Stating that TÜBİTAK has the task of coordinating vaccination studies, Mandal stated that the production will take place in companies.
Explaining that they will consult with companies and scientists during the process, Mandal said, “If I introduce something about the name that can be given to the vaccines, it will be like TUBITAK has put this name. said.
“WE CAN REACTION VERY FAST, OUR CONFIDENCE HAS BEEN BUILT”
Mandal, who stated that they designed a vaccine against variations in VLP based on virus-like particles, pointed out that the VLP design was renewed in one month against the British mutation.
Mandal stated that phase 2 studies will be carried out according to this mutation and continued as follows:
“We can react very quickly, we have self-confidence. Especially our President has carried this to the highest level. There are 2 new structures in the Economic Reform Package announced. It shows that Turkey cares about this area. This is actually not only about Covid-19, but medicines have not been developed yet, no treatment has been found for the diseases we may encounter or the diseases that may exist, and studies on them will be carried out. Many of our institutions have now assumed this task. we will feel both excited and responsible. “
Emphasizing that they want to attract scientists and researchers working in this field to Turkey through the International Leading Researchers Program, Mandal announced that 127 scientists and researchers from various fields have come to Turkey.